Clinical Trial Detail

NCT ID NCT01663259
Title Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Avraham Eisbruch
Indications

oropharynx cancer

Therapies

Cetuximab

Age Groups: adult

No variant requirements are available.